Compare ADMA Biologics Inc (ADMA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Raymond James Financial, Inc. — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Raymond James Financial, Inc. trades at $164.94 (market cap $32.66B). The key difference: Raymond James Financial, Inc. is far larger — about 15.3× ADMA Biologics Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | RJF | |
|---|---|---|
Market Cap | $2.13B | $32.66B |
Sector | Health | Financials |
52-Week High | $20.38 | $176.43 |
52-Week Low | $7.60 | $140.89 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Raymond James Financial (RJF) trades at $167.60, up 3.04% today, near its consensus price target of $168.00. The stock shows a bullish technical trend with strong moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth remains solid, climbing from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. Recent news highlights dividend declarations and record quarterly performance, reinforcing positive sentiment.
Outlook is cautiously optimistic with upside to the high target of $182.00, supported by earnings momentum and analyst coverage. Risks include rising expenses and market volatility. The stock presents a balanced opportunity for growth-oriented investors, though cost management remains a key watchpoint amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
